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Abstract We have previously shown that the human RNA
polymerase II subunit 11 (hRPB11) is among the proteins
specifically downregulated upon Doxorubicin (Dox) treatment of
human cancer cell lines, and that Dox resistant clones derived
upon drug selection express about 20% of the protein present in
the original parental cell line. Given the prominent role that this
subunit appears to have in eukaryotic cells, and the fact that its
deletion causes lethality in yeast, we wanted to test the effect of
the reintroduction of parental cell line levels of this subunit in
Dox resistant colon cancer cells (LoVoDX). Stable transfectants
of LoVoDX expressing parental (LoVoH) levels of hRPB11
showed a reduced sensitivity to the drug without changing the
response of these cells to other chemotherapeutic agents,
confirming a specific inverse correlation between cellular Dox
sensitivity anti-hRPB11 levels of expression. In addition we show
here that the levels of expression of this same RNA polymerase
II subunit directly affect cellular differentiation, reducing the
rate of cell proliferation, clonogenicity and increasing the
expression of E-cadherin, a marker of epithelial cell differentia-
tion. As expected from cells with these characteristics, upon in
vivo administration of these clones in nude mice, we detected a
significant reduction in the size and time of appearance of the
primary tumors and overall metastatic capability. Finally, the
role played by hRPB11 in regulating the transcription of specific
genes is underlined by transient transfection experiments that
show transactivation of the E-cadherin promoter by this protein.
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1. Introduction
One of the major obstacles encountered during cancer
chemotherapy is the emergence of cellular drug resistance
with consequent selection of more aggressive tumor pheno-
types. It has been shown that the appearance of this phenom-
enon is associated with altered expression of proto-oncogenes,
cell cycle and apoptosis regulating genes [1^5]. Doxorubicin
(Dox) is a widely used antineoplastic drug with a broad spec-
trum of chemotherapeutic activity on several malignancies [6],
but its use is often hampered by the surging of multidrug
resistance [7,8] and its cumulative dose-dependent cardiac tox-
icity, which leads to irreversible degenerative cardiomyopathy
[9].
We [10] and others [11,12] have shown that Dox exerts
speci¢c functions on the transcription machinery without af-
fecting housekeeping genes. In particular, regarding the myo-
cardium, it has been demonstrated that Dox negatively a¡ects
the transcription of heart-speci¢c genes [11^13]. Among the
causes of this phenomenon the induction of a dominant neg-
ative regulator of transcription has been observed [14]. These
latter ¢ndings have been postulated to play a pathogenic role
in the degenerative cardiomyopathy associated with Dox ad-
ministration.
Interestingly, among the genes speci¢cally a¡ected by Dox
administration, we have previously identi¢ed and cloned
hRPB11, a core subassembly subunit of RNA polymerase II
(RNA pol II) (for recent nomenclature see [15]) as the enzyme
involved in the synthesis of mRNA [16^18] and have shown
a dramatic correlation between Dox treatment and down-
modulation of this ubiquitous protein in di¡erent cell lines
[10]. Therefore we sought to investigate the possible correla-
tion between levels of expression of this subunit and Dox
cellular sensitivity and ultimately how Dox treatment could
in£uence the progression toward a more aggressive neoplastic
phenotype. We report here that reintroduction of parental
cell line (LoVoH) levels of hRPB11 in Dox resistant colon
cancer cell (LoVoDX) dramatically increases the cell sensitiv-
ity to this chemotherapeutic agent without a¡ecting the
response to other antineoplastic drugs. In addition, cells
stably transfected with hRPB11 show a profound modi¢ca-
tion of their phenotype accompanied by increased levels of
expression of E-cadherin and a less aggressive behavior when
administered in vivo. Finally the e¡ects of hRPB11 in
promoting speci¢c gene transcription are made tangible in
transient transfection experiments, showing that the E-cad-
herin promoter linked to a reporter gene is transactivated
when hRPB11 is cotransfected in the same cell. Taken to-
gether these ¢ndings suggest that a direct correlation exists
between hRPB11 levels of expression and Dox sensitivity and
that the same may also play a major role in cell di¡erentia-
tion.
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2. Materials and methods
2.1. Cells analysis of drug sensitivity and in vitro proliferation
Human colon carcinoma LoVoH and LoVoDX (Dox resistant
cells) were kindly provided by Dr. M.P. Colombo (Istituto Nazionale
Tumori, Milan, Italy). The establishment and characteristics of these
cells have already been described [13]. LoVoDX cells were maintained
by continuous exposure to 0.2 WM Dox (Adriblastina, Farmitalia
Carlo Erba, Milan, Italy). Drug sensitivity of LoVoDX transfectants
was evaluated by calculating the drug dose responsible for 50% in-
hibition of proliferation (IC50 value). Cells were plated in triplicate at
the density of 2U105 cells/60 mm diameter tissue culture dishes. After
24 h of incubation in Ham’s F12 (BioWhittaker, Verviers, Belgium)
supplemented with 10% fetal calf serum (Life Technologies, Gaithers-
burg, MD, USA), cells were treated with the appropriate drug con-
centrations. After 8 days, dishes were washed with PBS, cells were
detached by trypsin treatment and counted using a Coulter counter
model ZM (Coulter Electronics, Luton, UK). All cell lines were ex-
amined simultaneously and all experiments were performed at least
three times. Proliferation curves were obtained by plating 1U105 cells
into 60-mm diameter dishes. At daily intervals, cells were detached by
trypsin treatment and counted using a Coulter counter model ZM.
Doubling time was calculated from the exponential region of prolif-
eration curves. Clonogenic ability was evaluated by plating 5U102
cells into 60-mm dishes, so that colonies would appear after 8^10
days. Cells were ¢xed and stained with 0.5% Crystal Violet solution
containing 20% ethanol. Colonies consisting of s 50 cells were
counted using a light microscope. The clonogenic ability was calcu-
lated as percentage of colony numbers over plated cell number. All
experiments were performed at least three times with three samples for
each cell line.
2.2. Western blot analysis of hRPB11 and E-cadherin expression
Equal amounts of total cell lysates were separated on 12.5% poly-
acrylamide gel by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) [20]. Proteins were transferred to nitrocellulose (Amersham,
Bucks, UK) and blots were probed with a puri¢ed polyclonal anti-
hRPB11 antibody [10]. For E-cadherin analysis a 6% gel was used and
the blot was probed with a speci¢c monoclonal antibody anti-E-cad-
herin (Transduction Laboratories, Lexington, KY, USA). Immuno-
reactivity was detected using an enhanced chemiluminescence kit
(Amersham) as described by the manufacturer. Band intensity from
Western blot analysis was quanti¢ed using a GS-700 Imaging Densi-
tomer (Bio-Rad) and normalized to the relative HSP7O protein levels
detected with a speci¢c monoclonal antibody (W27, Santa Cruz Bio-
tech. Inc., Santa Cruz, CA, USA).
2.3. RT-PCR analysis of E-cadherin mRNAs
The analysis of E-cadherin mRNA expression was carried out as
previously described [21]. PCR products were electrophoresed onto a
1.5% agarose gel containing ethidium bromide (0.5 Wg/ml) and visual-
ized under UV light. The relative intensity of the bands was quanti¢ed
by densitometric analysis (GS-Imaging Densitometer, Bio-Rad, Her-
cules, CA, USA) and normalized to a co-ampli¢ed aldolase cDNA
fragment as previously reported [22]. At least 3 RT-PCR experiments
were performed using three di¡erent RNA preparations.
2.4. DNA transfections and analysis of E-cadherin promoter activity
LoVoDX cells overexpressing hRPB11 were obtained by stable
transfection using the expression vector pBK-hRPB11, made by ligat-
ing the entire hRPB11 cDNA into pBK-CMV (Stratagene, La Jolla,
CA, USA). Cells were transfected using the calcium phosphate pro-
cedure [23] and selected in 1 mg/ml G-418 for 10 days, and then
maintained at 0.6 mg/ml. Individual lines were derived by isolating
single primary colonies. LoVoDX cells were also transfected with the
empty vector pBK-CMV and the G418 resistant clones obtained were
used as control in all of the experiments performed. For the analysis
of the human E-cadherin promoter activity, transient transfection ex-
periments were performed using the luciferase reporter gene construct
pGL2 Ecad3/Luc containing E-cadherin 5P £anking sequences of 1484
bp, kindly provided by Dr. E.C. Fearon [24]. The pGL2-control lu-
ciferase reporter vector was obtained from Promega (Promega, Mad-
ison, WI, USA). The pCMVL plasmid, containing a functional LacZ
gene expressed under the control of the human cytomegalovirus im-
mediate early promoter, was obtained from Clontech (Clontech, Palo
Alto, CA, USA). LoVoDX cells growing at roughly 70% con£uence
were transfected in 60-mm plates with 3 Wg of the pGL2 plasmids,
3 Wg of pBK-CMV or pBK-hRPB11, and 0.5 Wg of pCMVL plasmid,
using the calcium phosphate procedure [23]. Cell extracts were pre-
pared 48 h post transfection using reporter lysis bu¡er (Promega).
One tenth of the lysate was used for the luciferase and L-galactosidase
assays, carried out as recommended by the manufacturers, Promega
and Tropix (Tropix, Bedford, MA, USA), respectively. Luciferase and
L-galactosidase activities were measured with a luminometer (model
MLX, Dynex Technologies, Chantilly, VA, USA). All transfections
were repeated at least three times.
2.5. Animals and in vivo experiments
Male CD-1 nude (nu/nu) mice (6^8 weeks old and 22^24 g in body
weight) were purchased from Charles River Laboratories, Calco,
Italy. Animals were kept under pathogen-free conditions in a laminar
air-£ow cabinet and fed with acidi¢ed, autoclaved water and Q-irradi-
ated commercial diet ad libitum. All manipulations were performed
under sterile conditions in a laminar air £ow hood. All procedures
involving animals were in accordance to institutional guidelines in
compliance with national and international laws and policies (EEC
Council Directive 86/109, OJL 358, December 1, 1987, and the Na-
tional Institute of Health (NIH) Guide for the Care and Use of Lab-
oratory Animals, NIH Publ. No. 85-23, 1985). LoVoDX and Lo-
VoDX-hRPB11 expressing cells in exponential phase of growth were
harvested, washed once with medium and resuspended in cold me-
dium without FCS. 5U106 viable cells, as evaluated by the trypan
blue exclusion test, were concentrated in 0.2 ml of serum-free medium
and injected into the hind leg muscles of the mice. Each experimental
group included ten mice. Neoplastic development was monitored and
tumor weights were calculated from caliper measurements according
to the formula: tumor weight (mg) = length (mm)Uwidth2 (mm)/2
[25]. To evaluate the metastatic ability, tumor-bearing mice were sac-
ri¢ced 120 days after tumor cell injection. Their lungs were removed
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Fig. 1. Transfection of LoVoDX cells with pBK-hRPB11 restores
LoVoH levels of expression of the protein. Top: Detection of
hRPB11 protein in LoVoDX stable transfectants. Protein lysates
were separated by SDS-PAGE and hRPB11 was detected by immu-
noblotting with a speci¢c polyclonal antibody [10]. Lane 1: recombi-
nant fusion protein used as hRPB11 positive control; lane 2: Lo-
VoDX cells stably transfected with empty vector, clone pBK-3;
lanes 3,4: hRPB11 stable transfectants clone alpha and gamma, re-
spectively; lane 5: LoVoH cells. Bottom: Results obtained on the
same blot with an anti-HSP70 monoclonal antibody.
Table 1
Doxorubicin sensitivity of transfected LoVoDX-hRPB11 cells








Experiments were performed as described in Section 2. IC50 values
correspond to the drug responsible for 50% of cell proliferation in-
hibition. Fold sensitivity corresponds to the ratio of IC50 parental
cells. The data shown represent the mean of three independent experi-
ments performed in triplicate.
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and ¢xed in Bouin’s solution to distinguish tumor nodules from lung
tissue, and the number of metastases was determined with the aid of a
dissecting microscope.
2.6. Statistical analysis
Statistical analysis was performed by the Mann-Whitney U test for
statistical signi¢cance. Di¡erences were considered signi¢cant at P
values 6 0.05 (two sided).
3. Results
3.1. Re-expression in LoVoDX cells of hRPB11 levels
We have previously shown that the level of hRPB11 protein
is decreased in LoVoDX resistant cells by about 80% when
compared to the parental cell line LoVoH [10]. To test our
hypothesis that this downregulation could play an important
role in Dox sensitivity, LoVoDX cells were transfected with
either pBK-hRPB11 or the empty vector pBK-CMV, and sta-
ble transfectants were generated. Three G418-resistant clones
derived from either PBK-hRPB11 or empty vector transfec-
tions were isolated and expanded for further analysis. In order
to con¢rm hRPB11 protein overexpression in transfected Lo-
VoDX cells, immunoblot analysis was performed using a pu-
ri¢ed anti-hRPB11 polyclonal antibody [10]. As shown in Fig.
1, hRPB11 transfected clones alpha and gamma expressed
much higher levels of hRPB11 protein than the control trans-
fected cells. In addition their level of expression was similar,
quantitatively, to the one present in Dox sensitive LoVoH
cells (Fig. 1, lane 5 and [10]). Clone beta expressed similar
levels on the protein (not shown).
3.2. hRPB11 overexpression speci¢cally a¡ects cellular
Dox sensitivity
To test if cellular sensitivity to Dox was correlated to the
levels of hRPB11 expression, we evaluated the pattern of Dox
sensitivity in hRPB11 transfectant and control clones. Table 1
shows that each stable transfected clone displayed an in-
creased sensitivity to Dox, with an IC50 ranging from 0.75
to 1.50 WM, remarkably lower than that of control tranfec-
tants pBK-1, pBK-2 and pBK-3, that essentially exhibited the
same IC50 of parental LoVoDX cells (4.0 WM). These obser-
vations clearly indicate that overexpression of hRPB11 con-
fers an increased sensitivity to Dox treatment. Since the de-
crease in sensitivity could be explained by e¡ects on the
MDR1 gene expression with resulting selective resistance to
drugs that are transported by this membrane pump [4], we
evaluated whether the transfection of hRPB11 a¡ected also
the sensitivity of hRPB11 transfectants to other antineoplastic
drugs. Table 2 shows that in these experiments the IC50 values
for all compounds tested did not indicate any signi¢cant dif-
ference between controls and hRPB11-transfected clones,
demonstrating that hRPB11 expression induces a very selec-
tive e¡ect on Dox sensitivity and thus suggesting that hRPB11
exerts its e¡ect through a speci¢c pathway not involving the
MDR1 gene.
3.3. hRPB11 overexpression a¡ects morphology of
LoVoDX cell
LoVoDX cells display a peculiar morphology, reminiscent
of less di¡erentiated phenotype, in respect to Dox sensitive
LoVoH cells [19]. Interestingly, when transfected with
hRPB11 LoVoDX cell clones grew in monolayers, displaying
cell clusters and epithelial-like sheets with a cellular polygonal
shape (Fig. 2, panel B) remarkably di¡erent from the
rounded-up shape of LoVoDX control cells (Fig. 2, panel
A), showing that hRPB11 overexpression profoundly a¡ects
the cellular phenotype. Similar morphological pro¢les were
obtained from each one of the hRPB11 transfectant clones
(not shown). These features are characteristic of a more di¡er-
entiated cell phenotype [26].
3.4. Growth inhibitory activity of hRPB11
These latter ¢ndings, underscoring additional roles for
hRPB11, prompted us to analyze the growth characteristics
of the hRPB11 transfectant clones. Table 3 shows that in
hRPB11 transfectant clones we observed an increase of dou-
bling time and a reduction of saturation density in compar-
ison to control clones and LoVoDX cells. To con¢rm the
growth inhibitory activity of hRPB11 we evaluated the clono-
genic ability of transfected clones. While we detected a de-
crease of about 50% of clonogenic ability in hRPB11 trans-
fected clones, we did not observe any di¡erence between
control transfectant clones and LoVoDX cells. In addition,
hRPB11 transfectant clones also exhibited a reduction in their
proliferative rate (not shown).
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Table 3







LoVoDX 18 þ 3 3.3 þ 0.2 18.4
pBK-1 22 þ 2 3.1 þ 0.4 16.5
pBK-2 21 þ 1 3.3 þ 0.3 16.3
pBK-3 20 þ 2 3.4 þ 0.5 15.8
alpha 34 þ 5 2.1 þ 0.2 10.6
beta 27 þ 3 2.0 þ 0.2 9.5
gamma 29 þ 5 2.1 þ 0.3 9.6
Experiments were performed as described in Section 2. Clonogenic
ability was evaluated as percentage of colony numbers over plated
cell number. The data shown represent the mean of three independent
experiments performed in triplicate.
Table 2
Drug sensitivity analysis of LoVoDX-hRPB11 transfectants
Drug IC50 (WM)
LoVoDX pBK-1 pBK-2 pBK-3 alpha beta gamma
Doxorubicin 4.10 4.00 4.20 4.20 1.50 1.00 0.75
Cisplatin 400 430 400 380 425 375 425
Etoposide 2.80 2.80 2.70 2.70 3.00 2.80 3.00
Actinomycin D 0.05 0.05 0.06 0.05 0.04 0.04 0.05
Vinblastine 0.05 0.05 0.04 0.04 0.06 0.05 0.05
Experiments were performed as described in Section 2. IC50 values correspond to the drug dose responsible for 50% inhibition of cell proliferation.
The data shown represent the mean of three independent experiments performed in triplicate.
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3.5. Transfection of hRPB11 increases E-cadherin expression
The downmodulation or disappearance of several markers
of di¡erentiation characterizes tumor progression. Among
these, E-cadherin [27] expression is found to be at a lower
level in poorly di¡erentiated colon carcinomas when com-
pared to either normal colon epithelium or well-di¡erentiated
colon carcinomas [28]. Furthermore, several studies have sug-
gested an inverse correlation between E-cadherin expression
and tumor grade [28^30]. We analyzed the E-cadherin expres-
sion at both the mRNA and protein levels in LoVoDX-
hRPB11 or control transfected cells. Table 4 shows that
hRPB11 overexpressing clones, when compared to controls,
displayed an increase of E-cadherin expression, con¢rming the
observation that overexpression of hRPB11 results in the ap-
pearance of a more di¡erentiated cellular phenotype.
3.6. HRPB11 overexpression reduces tumorigenicity
in nude mice
Since the overall data appeared to show that a more di¡er-
entiated in vitro phenotype was the result of hRPB11 over-
expression, we wanted to test the in vivo behavior of these
transfectants. To this purpose, we inoculated exponentially
growing cells of gamma and pBK-3 clones into nude mice
and followed the progression of tumor formation. As shown
in Table 5, tumor appearance was signi¢cantly delayed in
animals inoculated with gamma with respect to control cells.
Mice injected with 5U106 pBK-3 cells showed a palpable
tumor with a median time of 29 days after cell inoculation,
whereas 43 days (P = 0.032) were necessary to make the same
observation in the gamma cells injected mice. At day 50 after
tumor cell inoculation, the average weight of pBK-3-derived
tumors was 670 mg, whereas the tumor formed by the gamma
clone cells was 263 mg (P = 0.008). In addition an analysis of
spontaneous lung metastases evaluated by sacri¢cing the ani-
mals at 120 days after tumor cell injection, revealed that gam-
ma cell inoculated mice also showed a reduced number of
lung metastates (Table 5, P = 0.03). Thus, it appears that the
more di¡erentiated phenotype observed in vitro in hRPB11
overexpressing clones is paralleled in vivo by reduced tumor
growth and metastatic ability.
3.7. hRPB11 transactivates E-cadherin promoter
It has recently been shown that among the mechanisms
underlying the loss of E-cadherin expression in epithelial can-
cers, defects in transacting pathways play a major role [24].
Since an essential component of the basal transcription ma-
chinery. hRPB11 modulates E-cadherin levels of expression,
we proceeded to investigate if hRPB11 could be a speci¢c
transacting factor for the E-cadherin gene promoter. To this
purpose, we transiently transfected pBK-hRPB11 DNA to-
gether with E-cad3/Luc vector [24] into LoVoDX cells. The
hRPB11 cDNA increased the E-cadherin promoter activity
more than 8-fold over the basic reporter construct, when co-
transfected with Ecad3/Luc (Fig. 3). These ¢ndings imply that
hRPB11 has a direct role in regulating E-cadherin expression
through transcriptional mechanisms.
4. Discussion
The data presented in this paper show a speci¢c involve-
ment of hRPB11 expression in Dox mediated cellular toxicity,
the sensitivity to the drug being inversely correlated to the
levels of hRPB11. Moreover, we show that levels of this pro-
tein, a core element of the transcription apparatus, deeply
a¡ect cell di¡erentiation, changing cell proliferation, ex-
pression of peculiar markers, in vivo tumorigenicity and
metastatic capability. Finally, as expected from a molecule
involved in mRNA transcription, in the case of the E-cadherin
promoter hRPB11 acts as a transacting factor.
We have previously shown that Dox speci¢cally downregu-
lated the levels of hRPB11 either as a consequence of the
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Table 4







LoVoDX 2.20 ^ 1.20 2.5
pBK-1 2.32 5 1.23 2.5
pBK-2 2.15 ^ 1.23 9
pBK-3 2.40 9 1.25 4.1
alpha 3.44 56 1.74 45
beta 3.24 47 1.78 48
gamma 3.76 70 1.60 33
RT-PCR and Western blot analysis were performed as described in
Section 2. Data represent the OD ratio of mRNA or protein expres-
sion normalized to aldolase or HSP70, respectively. v% corresponds
to the percentage of increased expression over parental cells. The data
shown represent the mean of three independent experiments.
Fig. 2. hRPB11 transfectants display a more di¡erentiated pheno-
type. A: Cell morphology of pBK-3 cells. B: Cell morphology of
hRPB II transfectant cells, clone gamma. Compared to parental
LoVoDX and empty vector transfected cells, hRPB11 transfectants
displayed strong morphological modi¢cations, forming clusters and
epithelial like sheets.
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selection of Dox resistant clones or in the course of acute
administration to several human cell lines [10]. We show in
this report that the inverse is true, since restoration of
hRPB11 levels detected in non-Dox treated cells (LoVoH) is
responsible for a selective increase in cell sensitivity to this
chemotherapeutic agent which does not involve the product
of the MDR gene [7,8].
Dox, in addition to displaying speci¢c systemic toxic side
e¡ects [31^34], selectively impairs the function of several
genes. Indeed, it downmodulates sarcomeric K-actin, troponin
I, myosin light chain 2, the muscle speci¢c M isoform of
creatine kinase [11], MyoD and myogenin [12] and these ef-
fects have been associated with a speci¢c action of this drug at
the transcriptional level. The presence of Dox response ele-
ments in the 5P-region of the human Id2 gene [14] suggests a
selective e¡ect of the drug on the transcription machinery, as
further demonstrated by the inhibition of the transcriptional
activity of a crude preparation of RNA pol II [35]. Moreover,
it has recently been demonstrated that the presence of the
drug in the culture medium can induce transcription from
promoters of immediate early genes through an AP-1-inde-
pendent pathway [36]. Since we have previously shown that
the di¡erences in gene expression due to a change in hRPB11
levels are not generalized, as well as the overall transcription
rate of housekeeping genes is not changed [10], we suggest
that the modulation of hRPB11 observed in Dox resistant
cells could be the result of the induction of a speci¢c pathway
in response to the Dox stress, and that the presence of low
levels of hRPB11 can confer a diminished drug sensitivity to
the cell.
In addition, hRPB11 stable transfected cells exhibited a
lower proliferative rate and reduced clonogenic ability. Lo-
VoDX cells overexpressing hRPB11 underwent deep altera-
tions in their morphology, displaying increased levels of
E-cadherin, the latter due to an increase in transcription
most likely the result of an e¡ect of hRPB11 on the E-cad-
herin promoter. In cancers of epithelial origin, loss of E-cad-
herin expression has been associated with the loss of di¡er-
entiated features in tumor cells and/or increased propensity of
the cells to invade and metastasize to distant sites [37]. The
restoration of E-cadherin expression, following E-cadherin
gene transfer, has also been shown to inhibit the invasive
and metastatic properties of cells in vitro and animal model
systems [38^40].
In agreement with the in vitro data, the evidence of a more
di¡erentiated phenotype was proved in vivo, where hRPB11
transfected cells showed reduced tumorigenicity and meta-
static ability when inoculated in nude mice.
Thus, taken together, these ¢ndings imply that the levels of
expression of hRPB11 act as ¢ne regulators of cell di¡erentia-
tion through the transcriptional recruitment of speci¢c genes.
In order to explain how a subunit of the general transcrip-
tion machinery could achieve such a result, several consider-
ations have to be made. Although hRPB11 is essential for cell
viability [41], levels of expression of this protein vary among
di¡erent tissues with the heart and skeletal muscle expressing
the highest [10]. hRPB11 shares a limited amino acid sequence
similarity with the K subunit of Escherichia coli RNA polym-
erase and interacts with another human RNA pol II K-like
subunit hRPB3. This heterodimer is considered the functional
counterpart of bacterial K subunit homodimer [42,43]. The
eubacterial K subunit performs at least three critical func-
tions: it serves as the initiator for RNA polymerase assembly,
it participates in promoter recognition by sequence-speci¢c
protein-DNA interaction, and it is the target for transcrip-
tional regulation by binding to a speci¢c set of transcriptional
activator proteins [15,44,45]. This last function is mediated by
the C-terminal part of the protein that binds DNA as an
isolated entity in a region between 342 and 362 bp, upstream
of the transcriptional start site [46]. Although eukaryotic K
subunits lack signi¢cant homologies with this COOH-terminal
of prokaryotic K subunits that plays a role in transcriptional
activation, the presence of a highly charged C-terminal £ank-
ing sequence in hRPB11 subunit suggests that this domain, in
addition to the conserved K-like domain, could be functionally
important for interaction with other transcription factors.
Moreover, the cnjC gene product, a homologue of the other
K-like RNA pol II subunit hRPB3 in Tetrahymena, has been
found active only during early conjugation, suggesting that it
may be involved in the regulation of transcription at this time
[47]. Although recently the hRPB11 subunit has been shown
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Fig. 3. Relative luciferase activity of the Ecad/Luc and control con-
structs in the presence or absence of hRPB11 expression vector in
LoVoDX cells. Luciferase activities were determined by triplicate
transfections of LoVoDx cells with the indicated luciferase con-
struct, a CMV-LacZ control construct, and where indicated, the
hRPB11 expression vector. All luciferase activities were normalized
for L-galactosidase activity. Filled columns: LoVoDX transfected
with Ecad3/Luc. Open columns: LoVoDX transfected with pGL2
control plasmid. Bars: S.D.
Table 5
In vivo tumorigenicity and metastatic behavior of a LoVoDX-hRPB11 transfectant
Cells Median latency of tumor
appearance in days (range)
Tumor weights (mg) þ S.D. Number of spontaneous metastases
(range)
LoVoDX pBK-3 29 (27^41) 670 þ 228 50 (40^60)
LoVoDX gamma 43 (34^45)* 263 þ 43** 32 (20^37)
Male CD-1 nude mice were injected into the hind leg with 5U106 cells. Tumor weights were assessed at day 50 after cell inoculation, lung
metastases at day 120. Each experimental group included 10 mice. *P6 0.05; **P6 0.01.
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to form a core subassembly subunit of RNA pol II with DNA
binding activity [48], to date the function of this protein has
remained elusive.
Based on these observations, on the e¡ects of hRPB11 over-
expression observed in LoVoDX cells and on the fact that the
expression of hRPB11 exhibits a tissue-speci¢c pattern in nor-
mal tissues [10], we speculate that hRPB11 may exert its spe-
ci¢c activity on gene regulation in a manner not dissimilar
from the one recently described for other core promoter ele-
ments that mediate preferential transcription of speci¢c pro-
moters [49,50]. We therefore hypothesize that this protein may
play a regulatory function in transcription by varying its stoi-
chiometry with other RNA pol II subunits and/or core pro-
moter elements, resembling in certain instances the function of
bacterial c factors [51].
Further investigations of the hRPB11 transfected clones
will allow us to determine which genes are speci¢cally modu-
lated by hRPB11 overexpression and will help to de¢ne more
precisely the function of this eukaryotic RNA pol subunit in
the processes of gene transcription and its regulation.
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